Connect
← Return to Weighing the cancer risk reduction & quality-of-life cost of ADT?
Discussion
Weighing the cancer risk reduction & quality-of-life cost of ADT?
Prostate Cancer | Last Active: Feb 13 5:00pm | Replies (123)Comment receiving replies
Hi Jeff. Please check out Dr. Kishan's presentation on RT and ADT in the attached Youtube video link: https://www.youtube.com/watch
Towards the end , on a page titled ADT Meta-Analysis, he shows ADT improves both overall ten year survival and metastisis-free survival rates by 9% and 8 % respectivley, and then adds for intermediate risk patients we have to treat 18 patients to benefit 1, and for high risk patients, we have to treat 8.4 to benefit 1.
I could be wrong, but I understand this to mean roughly 1 in 8 high risk patients like me gain cancer control or life-prolonging benefit from ADT. That is because I am assuming Dr. Kishan is here giving us the Number Needed to Tread (NNT) number for ADT. And the way I understand it, NNT gives the average number of patients who must receive treatment for one patient to experience the expected beneift of the treatment.
I have already set up a consultation appointement with him for December 9th , and this is one of the many questions I will ask him since - as he clearly sated in the video- he strongly believes in adding ADT to RT, and since he also beleives an NNT number of 8 or 10 is very good in the medical field (which is very counter-intuitive to folks like me).
Replies to "@jeffmarc Hi Jeff. Please check out Dr. Kishan's presentation on RT and ADT in the attached..."
Connect
@soli
I listened to the video. His opinion of ADT was that it was beneficial.
The exact words were
‘How many men do you have to treat to Prevent distant metastasis in one man the number is 18.4 for intermediate disease and 8.4 for high risk disease. In oncology, we consider these good numbers and pretty effective intervention. In many cancers there are no therapies that have that big impact. While it has a lot of side effects. It does work.”
He also posted the standard ADT recommendation of intermediate risk 4 to 6 months high risk treated with EBRT 18 to 36 months and EBRT+ Brachytherapy 12-36 months.
He did not say ADT should not be used.